Assessing the Importance of Treatment Goals in Patients with Psoriasis: Analytic Hierarchy Process vs. Likert Scales

  • Mandy Gutknecht
  • Marion Danner
  • Marthe-Lisa Schaarschmidt
  • Christian Gross
  • Matthias Augustin
Original Research Article
  • 19 Downloads

Abstract

Background

To define treatment benefit, the Patient Benefit Index contains a weighting of patient-relevant treatment goals using the Patient Needs Questionnaire, which includes a 5-point Likert scale ranging from 0 (“not important at all”) to 4 (“very important”). These treatment goals have been assigned to five health dimensions. The importance of each dimension can be derived by averaging the importance ratings on the Likert scales of associated treatment goals.

Objective

As the use of a Likert scale does not allow for a relative assessment of importance, the objective of this study was to estimate relative importance weights for health dimensions and associated treatment goals in patients with psoriasis by using the analytic hierarchy process and to compare these weights with the weights resulting from the Patient Needs Questionnaire. Furthermore, patients’ judgments on the difficulty of the methods were investigated.

Methods

Dimensions of the Patient Benefit Index and their treatment goals were mapped into a hierarchy of criteria and sub-criteria to develop the analytic hierarchy process questionnaire. Adult patients with psoriasis starting a new anti-psoriatic therapy in the outpatient clinic of the Institute for Health Services Research in Dermatology and Nursing at the University Medical Center Hamburg (Germany) were recruited and completed both methods (analytic hierarchy process, Patient Needs Questionnaire). Ratings of treatment goals on the Likert scales (Patient Needs Questionnaire) were summarized within each dimension to assess the importance of the respective health dimension/criterion. Following the analytic hierarchy process approach, consistency in judgments was assessed using a standardized measurement (consistency ratio).

Results

At the analytic hierarchy process level of criteria, 78 of 140 patients achieved the accepted consistency. Using the analytic hierarchy process, the dimension “improvement of physical functioning” was most important, followed by “improvement of social functioning”. Concerning the Patient Needs Questionnaire results, these dimensions were ranked in second and fifth position, whereas “strengthening of confidence in the therapy and in a possible healing” was ranked most important, which was least important in the analytic hierarchy process ranking. In both methods, “improvement of psychological well-being” and “reduction of impairments due to therapy” were equally ranked in positions three and four. In contrast to this, on the level of sub-criteria, predominantly a similar ranking of treatment goals could be observed between the analytic hierarchy process and the Patient Needs Questionnaire. From the patients’ point of view, the Likert scales (Patient Needs Questionnaire) were easier to complete than the analytic hierarchy process pairwise comparisons.

Conclusions

Patients with psoriasis assign different importance to health dimensions and associated treatment goals. In choosing a method to assess the importance of health dimensions and/or treatment goals, it needs to be considered that resulting importance weights may differ in dependence on the used method. However, in this study, observed discrepancies in importance weights of the health dimensions were most likely caused by the different methodological approaches focusing on treatment goals to assess the importance of health dimensions on the one hand (Patient Needs Questionnaire) or directly assessing health dimensions on the other hand (analytic hierarchy process).

Notes

Acknowledgements

We thank the team of the psoriasis clinic at the University Medical Center Hamburg for their support in the patients’ recruitment and Mario Gehoff and Sara Tiedemann for copy editing this manuscript. We also thank all the patients for their participation.

Author contributions

MG designed and conducted the study, analyzed and interpreted study data, and drafted the manuscript. MD supported the study conception and design and data analyses, and contributed to the interpretation of data and critical revision of the manuscript. MLS contributed to the study conception and design, and critical revision of the manuscript. CG supported data analyses and contributed to the critical revision of the manuscript. MA contributed to the study conception and design, acquisition, and interpretation of data, and critical revision of the manuscript. MG acts as the guarantor for the content of the paper.

Compliance with Ethical Standards

Conflict of interest

Mandy Gutknecht has received financial support for participation in conferences from Abbvie and Astellas, and obtained honoria from Novartis. Marion Danner has no conflict of interest directly relevant to the content of this study. Marthe-Lisa Schaarschmidt conducted clinical trials for Abbvie, Boehringer Ingelheim, Celgene, Eli Lilly, Merck, Novartis, and UCB Pharma; obtained honoraria from Janssen-Cilag and Novartis; and received financial support for participation in conferences from Abbvie, ALK-Abello, Biogen, Janssen-Cilag, and MSD. Christian Gross is employed by a pharmaceutical company called Basics GmbH, which is a subsidiary of Sun Pharmaceuticals Industries Ltd. Sun Pharmaceutical Industries Ltd. sales manufactures drugs for the treatment of psoriasis. Matthias Augustin has no conflict of interest directly relevant to the content of this study.

Ethics approval

This non-interventional study was approved by the local ethics committee (reference number: PV5182).

Consent to participate

Surveyed patients in the study gave their informed consent.

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Supplementary material

40271_2018_300_MOESM1_ESM.pdf (1.9 mb)
Supplementary material 1 (PDF 1997 kb)

References

  1. 1.
    Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–85.  https://doi.org/10.1038/jid.2012.339.CrossRefPubMedGoogle Scholar
  2. 2.
    de Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc. 2004;9:140–7.  https://doi.org/10.1046/j.1087-0024.2003.09110.x.CrossRefPubMedGoogle Scholar
  3. 3.
    Augustin M, Radtke MA, Zschocke I, Blome C, Behechtnejad J, Schafer I, et al. The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases. Arch Dermatol Res. 2009;301:561–71.  https://doi.org/10.1007/s00403-009-0928-8.CrossRefPubMedGoogle Scholar
  4. 4.
    Blome C, Augustin M, Behechtnejad J, Rustenbach SJ. Dimensions of patient needs in dermatology: subscales of the patient benefit index. Arch Dermatol Res. 2011;303:11–7.  https://doi.org/10.1007/s00403-010-1073-0.CrossRefPubMedGoogle Scholar
  5. 5.
    Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Allgemeine Methoden. Version 5.0 vom 10.07. 2017. http://www.iqwig.de/download/Allgemeine-Methoden_Version-5-0.pdf. Accessed 5 Dec 2017.
  6. 6.
    Saaty TL. The analytic hierarchy process: planning, priority setting, resource allocation. New York: McGraw-Hill; 1980.Google Scholar
  7. 7.
    Mulye R. An empirical comparison of three variants of the AHP and two variants of conjoint analysis. J Behav Decis Mak. 1998;11:263–80. doi: 10.1002/(SICI)1099-0771(1998120)11:4<263:AID-BDM301>3.0.CO;2-T.Google Scholar
  8. 8.
    Saaty TL. Decision making with the analytic hierarchy process. Int J Serv Sci. 2008;1:83–98.Google Scholar
  9. 9.
    Schmidt K, Aumann I, Hollander I, Damm K, von der Schulenburg JM. Applying the analytic hierarchy process in healthcare research: a systematic literature review and evaluation of reporting. BMC Med Inform Decis Making. 2015;15:112.  https://doi.org/10.1186/s12911-015-0234-7.CrossRefGoogle Scholar
  10. 10.
    Hummel M, Ijzerman M. The past and the future of the AHP in health care decision making. 2011. https://ris.utwente.nl/ws/portalfiles/portal/5454352. Accessed 30 Jun 2017.
  11. 11.
    Gutknecht M, Schaarschmidt M-L, Herrlein O, Augustin M. A systematic review on methods used to evaluate patient preferences in psoriasis treatments. J Eur Acad Dermatol Venereol. 2016;30:1454–64.  https://doi.org/10.1111/jdv.13749.CrossRefPubMedGoogle Scholar
  12. 12.
    Danner M, Vennedey V, Hiligsmann M, Fauser S, Gross C, Stock S. Comparing analytic hierarchy process and discrete choice experiment to elicit patient preferences for treatment characteristics in age-related macular degeneration. Value Health. 2017;20(8):1166–73.  https://doi.org/10.1016/j.jval.2017.04.022.CrossRefPubMedGoogle Scholar
  13. 13.
    Schmidt K, Babac A, Pauer F, Damm K, von der Schulenburg JM. Measuring patients’ priorities using the analytic hierarchy process in comparison with best-worst-scaling and rating cards: methodological aspects and ranking tasks. Health Econ Rev. 2016;6:50.  https://doi.org/10.1186/s13561-016-0130-6.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Muhlbacher AC, Bethge S, Kaczynski A, Juhnke C. Objective criteria in the medicinal therapy for type II diabetes: an analysis of the patients’ perspective with analytic hierarchy process and best-worst scaling. Gesundheitswesen. 2016;78:326–36.  https://doi.org/10.1055/s-0034-1390474.PubMedGoogle Scholar
  15. 15.
    Ijzerman MJ, van Til JA, Bridges JFP. A comparison of analytic hierarchy process and conjoint analysis methods in assessing treatment alternatives for stroke rehabilitation. Patient. 2012;5:45–56.  https://doi.org/10.2165/11587140-000000000-00000.CrossRefPubMedGoogle Scholar
  16. 16.
    Ijzerman MJ, van Til JA, Snoek GJ. Comparison of two multi-criteria decision techniques for eliciting treatment preferences in people with neurological disorders. Patient. 2008;1:265–72.  https://doi.org/10.2165/01312067-200801040-00008.CrossRefPubMedGoogle Scholar
  17. 17.
    van Til JA, Dolan JG, Stiggelbout AM, Groothuis KCGM, Ijzerman MJ. The use of multi-criteria decision analysis weight elicitation techniques in patients with mild cognitive impairment: a pilot study. Patient. 2008;1:127–35.  https://doi.org/10.2165/01312067-200801020-00008.CrossRefPubMedGoogle Scholar
  18. 18.
    Osoba D, Hsu M-A, Copley-Merriman C, Coombs J, Johnson FR, Hauber B, et al. Stated preferences of patients with cancer for health-related quality-of-life (HRQOL) domains during treatment. Qual Life Res. 2006;15:273–83.  https://doi.org/10.1007/s11136-005-0580-5.CrossRefPubMedGoogle Scholar
  19. 19.
    Johnson FR, Hauber AB, Osoba D, Hsu M-A, Coombs J, Copley-Merriman C. Are chemotherapy patients’ HRQoL importance weights consistent with linear scoring rules? A stated-choice approach. Qual Life Res. 2006;15:285–98.  https://doi.org/10.1007/s11136-005-0581-4.CrossRefPubMedGoogle Scholar
  20. 20.
    Hauber AB, Mohamed AF, Johnson FR, Oyelowo O, Curtis BH, Coon C. Estimating importance weights for the IWQOL-Lite using conjoint analysis. Qual Life Res. 2010;19:701–9.  https://doi.org/10.1007/s11136-010-9621-9.CrossRefPubMedGoogle Scholar
  21. 21.
    Clay RA. The link between skin and psychology. 2015. Available from: http://www.apa.org/monitor/2015/02/cover-skin.aspx. Accessed 26 Jul 2017.
  22. 22.
    Dolan JG, Jr Isselhardt BJ, Cappuccio JD. The analytic hierarchy process in medical decision making: a tutorial. Med Decis Making. 1989;9:40–50.CrossRefPubMedGoogle Scholar
  23. 23.
    Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Arbeitspapier: Analytic Hierarchy Process (AHP): Pilotprojekt.2013.http://www.iqwig.de/de/projekte-ergebnisse/projekte/gesundheitsoekonomie/ga10-01-pilotstudie-analytic-hierarchy-process-in-der-indikation-majore-depression.1409.html. Accessed 4 Jan 2018.
  24. 24.
    Orme BK. Getting started with conjoint analysis: strategies for product design and pricing research. 2nd ed. Madison: Research Publishers LLC; 2010.Google Scholar
  25. 25.
    Hummel JM, Bridges JFP, Ijzerman MJ. Group decision making with the analytic hierarchy process in benefit-risk assessment: a tutorial. Patient. 2014;7:129–40.  https://doi.org/10.1007/s40271-014-0050-7.CrossRefPubMedGoogle Scholar
  26. 26.
    Forman E, Peniwati K. Aggregating individual judgments and priorities with the analytic hierarchy process. Eur J Operational Res. 1998;108:165–9.  https://doi.org/10.1016/S0377-2217(97)00244-0.CrossRefGoogle Scholar
  27. 27.
    Danner M, Vennedey V, Hiligsmann M, Fauser S, Gross C, Stock S. How well can analytic hierarchy process be used to elicit individual preferences? Insights from a survey in patients suffering from age-related macular degeneration. Patient. 2016;9(5):481–92.  https://doi.org/10.1007/s40271-016-0179-7.CrossRefPubMedGoogle Scholar
  28. 28.
    Pauer F, Schmidt K, Babac A, Damm K, Frank M, von der Schulenburg JM. Comparison of different approaches applied in analytic hierarchy process: an example of information needs of patients with rare diseases. BMC Med Inform Decis Mak. 2016;16:117.  https://doi.org/10.1186/s12911-016-0346-8.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Institute for Health Services Research in Dermatology and Nursing (IVDP), German Center for Health Services Research in Dermatology (CVderm)University Medical Center Hamburg-Eppendorf (UKE)HamburgGermany
  2. 2.Institute for Health Economics and Clinical Epidemiology (IGKE)University Hospital of Cologne (AöR)CologneGermany
  3. 3.Department of Dermatology, University Medical Center MannheimUniversity of HeidelbergMannheimGermany
  4. 4.Basics GmbHLeverkusenGermany

Personalised recommendations